Prime Medicine
PRME
187 hedge funds and large institutions have $393M invested in Prime Medicine in 2026 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 64 increasing their positions, 67 reducing their positions, and 23 closing their positions.
15% more capital invested
Capital invested by funds: $343M → $393M (+$50.9M)
4.46% more ownership
Funds ownership: 54.59% → 59.05% (+4.5%)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
0% less call options, than puts
Call options by funds: $2.84M | Put options by funds: $2.85M
4% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 67
3% less funds holding
Funds holding: 192 → 187 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.17M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.98M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.71M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$4.12M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2.47M |
| 2 |
Renaissance Technologies
New York
|
-$2.07M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$1.77M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.75M |
| 5 |
HF
HRT Financial
New York
|
-$1.5M |
PRME Hedge Fund Activity: Q2 2026 in Review
187 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2026, worth a combined $393M — up 15% from $343M a quarter earlier.
Fund positioning in PRME was balanced in Q2 2026: 23 funds opened new positions, 23 closed out, 64 added to existing stakes and 67 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.17M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.47M.
- 187 institutional investors held Prime Medicine (PRME) as of Q2 2026, down from 192 in Q1 2026.
- Funds reported $393M of Prime Medicine stock for Q2 2026, up 15% quarter-over-quarter.
- 23 funds opened new Prime Medicine positions in Q2 2026 and 23 closed out, a net change of 0 holders.
- The largest Prime Medicine buyer in Q2 2026 was Goldman Sachs, an estimated $8.17M added.
- The largest Prime Medicine seller in Q2 2026 was D.E. Shaw & Co, an estimated $2.47M sold.
Based on aggregated 13F filings for Q2 2026.